香雪品牌怎么样 申请店铺

我要投票 香雪在中草药行业中的票数:352 更新时间:2025-05-10
香雪是哪个国家的品牌?「香雪」是 广州市香雪制药股份有限公司 旗下著名品牌。该品牌发源于广东,由创始人王永辉在1986期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力香雪品牌出海!将品牌入驻外推网,定制香雪品牌推广信息,可以显著提高香雪产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

香雪怎么样

广州市香雪制药股份有限公司总部位于广州经济技术开发区科学城,是一家以中成药制药和研发为主业,集西药制药、生物医学工程和药材规范种植于一体的现代化高新技术医药企业。

公司秉承“厚生臻善维新”的企业理念,坚持“崇尚品质;关爱健康”的质量方针,坚持自主创新、自主品牌,在品质、技术、研发、品牌和规模等多方面成长为行业领先者,得到消费者、行业和政府主管部门的高度评价和广泛认可,其中“香雪”商标获评中国驰名商标,“香雪抗病毒口服液”获评广东省名牌和广州市名牌产品,香雪制药获评“《福布斯》中国成长企业潜力榜100强”前五位,香雪制药获评“广东省医药产业50强企业”和“广州2010年亚运会药品供应商”等。

香雪制药一直致力于质量创新,致力于中药现代化的研究和实践,1998年开始进行中药现代化关键技术指纹图谱质量控制技术的研究,并取得重大突破。2001年,香雪抗病毒口服液指纹图谱质控研究被纳入广州名优中成药品种指纹图谱质量控制示范研究项目。2000年,香雪制药本着“实施中药系列标准规范,提高中成药品种质量”的理念,承担了国家科技部的“九五”重点科技攻关项目广藿香GAP种植基地,经过一年多的探索与研究,现已被国家科技部列入第一批国家中药现代化科技产业化(广东)基地,并通过国家验收。

香雪制药本着高起点、高技术、高标准、高速度的现代企业发展战略,采用先进的技术、工艺、设备,形成了完善、科学、先进的生产体系,使公司的产品质量和主要技术指标均达到了国内先进水平。公司坚持“创新”为企业的灵魂,以科技进步推动企业的发展。近年来承担了多项国家及省、市级重大科技专项技术的研究与开发;本着生产一代、储备一代、研制一代、构思一代的新产品开发战略。加快了疗效确切、科技含量高的新产品的研制开发。

Guangzhou Xiangxue Pharmaceutical Co., Ltd., headquartered in Science City, Guangzhou Economic and Technological Development Zone, is a modern high-tech pharmaceutical enterprise with Chinese patent medicine and R & D as its main business, integrating western medicine, biomedical engineering and standard planting of medicinal materials. The company adheres to the enterprise concept of "great life, perfect and innovative", and adheres to "advocating quality"; The company adheres to the quality policy of "care for health", adheres to independent innovation and independent brand, grows into the industry leader in quality, technology, R & D, brand and scale, and is highly appraised and widely recognized by consumers, industry and government authorities. Among them, "Xiangxue" trademark is awarded the famous trademark in China, and "Xiangxue antiviral oral liquid" is awarded the famous brand in Guangdong Province and Guangzhou city Brand products, Xiangxue pharmaceutical won the top five "Forbes China growth enterprise potential list top 100", Xiangxue pharmaceutical won the "top 50 pharmaceutical enterprises in Guangdong Province" and "drug supplier of Guangzhou 2010 Asian Games" and so on. Xiangxue pharmaceutical has been committed to quality innovation, research and practice of the modernization of traditional Chinese medicine. In 1998, it began to study the key technology of the modernization of traditional Chinese medicine fingerprint quality control technology, and made a major breakthrough. In 2001, the fingerprint quality control research of Xiangxue antiviral oral liquid was included in the quality control demonstration research project of Guangzhou famous and excellent Chinese patent medicine. In 2000, in line with the concept of "implementing the standards and specifications of traditional Chinese medicine series and improving the quality of traditional Chinese medicine varieties", Xiangxue pharmaceutical undertook the patchouli gap planting base, a key scientific and technological key project of the Ninth Five Year Plan of the Ministry of science and technology of the people's Republic of China. After more than a year's exploration and research, it has been listed in the first batch of national bases for the modernization of science and technology industrialization of traditional Chinese medicine (Guangdong) by the Ministry of science and technology of the people's Republic of China and passed the national acceptance 。 Based on the modern enterprise development strategy of high starting point, high technology, high standard and high speed, Xiangxue pharmaceutical adopts advanced technology, process and equipment to form a perfect, scientific and advanced production system, so that the product quality and main technical indicators of the company have reached the advanced level in China. The company adheres to "innovation" as the soul of the enterprise and promotes the development of the enterprise with the progress of science and technology. In recent years, it has undertaken the research and development of a number of national, provincial and municipal major science and technology special technologies; in line with the new product development strategy of production generation, storage generation, development generation and conception generation. The research and development of new products with precise curative effect and high technology content are accelerated.

本文链接: https://brand.waitui.com/f0447df2d.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

2025年4月份居民消费价格同比下降0.1%

2025年4月份,全国居民消费价格同比下降0.1%。其中,城市持平,农村下降0.3%;食品价格下降0.2%,非食品价格持平;消费品价格下降0.3%,服务价格上涨0.3%。1—4月平均,全国居民消费价格比上年同期下降0.1%。 4月份,全国居民消费价格环比上涨0.1%。其中,城市上涨0.2%,农村持平;食品价格上涨0.2%,非食品价格上涨0.1%;消费品价格持平,服务价格上涨0.3%。(国家统计局)

2小时前

2025年4月份工业生产者出厂价格同比下降2.7%

2025年4月份,全国工业生产者出厂价格同比下降2.7%,环比下降0.4%;工业生产者购进价格同比下降2.7%,环比下降0.6%。1—4月平均,工业生产者出厂价格和购进价格比上年同期均下降2.4%。(国家统计局)

2小时前

海南EF账户业务量超1200亿元

5月9日举行的人民银行海南省分行2025年第二季度新闻发布会披露,海南自贸港多功能自由贸易账户(EF账户)业务持续增长,截至5月8日,海南10家试点银行累计开立EF账户330余个,全省EF账户业务量1200余亿元人民币。目前,海南自贸港EF账户资金划转应用较多的业务场景主要有跨境贸易结算、即期远期结售汇、流动资金贷款、境外放款、境外投资、外商投资等业务场景。(e公司)

2小时前

摩根士丹利招惠混合基金发布可能触发基金合同终止情形的第二次提示性公告

5月10日摩根士丹利基金公告称,截至5月9日,摩根士丹利招惠混合基金已连续40个工作日出现基金资产净值低于5000万元。若连续50个工作日出现基金份额持有人数量不满200人或基金资产净值低于5000万元情形,该基金将根据约定进行基金财产清算并终止,而无需召开基金份额持有人大会。摩根士丹利招惠混合基金成立于2021年5月,募集规模2.71亿元,截至今年一季度末规模不足5000万元。截至目前,该基金A份额成立以来亏损约5.51%。(e公司)

2小时前

福建省永泰县人民政府与大禹节水集团等签署永泰县全域土地综合整治—永福灌区项目合作框架协议

5月8日,福建省福州市永泰县政府与中国水利水电第十六工程局有限公司、中国电建集团华东勘测设计研究院有限公司、大禹节水集团股份有限公司签署永泰县全域土地综合整治—永福灌区项目合作框架协议。根据合作协议,四方将把灌区工程与土地综合整治项目紧密结合,确保项目从设计到运维管护全周期无缝衔接,形成“规划设计—投融资—建设施工—运营管护”的全产业链闭环,努力将项目打造成“田成方、林成网、渠相通、路相连、旱能灌、涝能排”的全省示范项目。(e公司)

2小时前

本页详细列出关于香雪的品牌信息,含品牌所属公司介绍,香雪所处行业的品牌地位及优势。
咨询